Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial
Jingxin Li(Beijing Tongren Hospital), Fengcai Zhu(Jiangsu Provincial Center for Disease Control and Prevention), Hongxing Pan(Jiangsu Provincial Center for Disease Control and Prevention), Shipo Wu(Academy of Military Medical Sciences), Lairun Jin(Southeast University), Fengjuan Shi(Jiangsu Provincial Center for Disease Control and Prevention), Lunbiao Cui(Jiangsu Provincial Center for Disease Control and Prevention), Lihua Hou(Academy of Military Medical Sciences), Tao Zhu, Jiahong Zhu, Xue Wang(CanSino (China)), Pengfei Jin(Jiangsu Provincial Center for Disease Control and Prevention), Junqiang Li(China Pharmaceutical University), Yin Chen(Beth Israel Deaconess Medical Center), Jingxian Liu(Jiangsu Provincial Center for Disease Control and Prevention), Xiaoyu Xu, Xuewen Wang(Shenzhen University Health Science Center), Jingxuan Wan(CanSino (China)), Wei Chen(Sun Yat-sen University), Xiling Guo(Jiangsu Provincial Center for Disease Control and Prevention), Zhizhou Song
Cited by 163
Related Papers
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
|The Lancet Infectious Diseases|2020|1.5k
Co-infection with respiratory pathogens among COVID-2019 cases
|Virus Research|2020|637
Serum Cytokine and Chemokine Profile in Relation to the Severity of Coronavirus Disease 2019 in China
|The Journal of Infectious Diseases|2020|391
A Family Cluster of Infections by a Newly Recognized Bunyavirus in Eastern China, 2007: Further Evidence of Person-to-Person Transmission
|Clinical Infectious Diseases|2011|268
An integrative drug repositioning framework discovered a potential therapeutic agent targeting COVID-19
|Signal Transduction and Targeted Therapy|2021|204